指南与共识泌尿与男性生殖病理

ISUP共识会议工作组1:膀胱癌分级系统性能比较

International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 1: Comparison of Bladder Cancer Grading System Performance.
指南 / 共识 · Am J Surg Pathol · 2023-05-29

国际泌尿病理学会(ISUP)2022年巴塞尔共识会议工作组1比较了WHO 2004与1973膀胱癌分级系统的应用现状与性能。通过调查病理医生和泌尿科医生、文献综述及现场投票,发现北美与欧洲在分级方案使用及低度恶性潜能乳头状尿路上皮肿瘤诊断上存在差异,但共同倾向于将WHO 2004高级别细分为临床相关类别的3级方案。

要点

  • WHO 2004与1973分级系统在全球范围内最常用,分级是非肌层浸润性乳头状尿路上皮癌进展的关键预后因素。
  • 调查显示北美与欧洲病理医生在分级方案选择及低度恶性潜能乳头状尿路上皮肿瘤诊断上存在明显差异。
  • 共识倾向将当前分级细化为3级方案,即将WHO 2004高级别分为临床相关类别。

核心结论

  • 调查与投票显示强烈倾向于将当前分级细化为3级方案,即将WHO 2004高级别分为临床相关类别。
  • 关于低度恶性潜能乳头状尿路上皮癌的使用,意见较为不一。

研究设计与样本

  • ISUP与欧洲泌尿外科协会合作开发了10个问题的调查,面向其成员了解病理医生和泌尿科医生当前使用的分级方案。
  • 另向ISUP成员发放调查,了解分级观察者间变异、尿细胞学报告及分级分配中的挑战。
  • 对膀胱癌分级预后、观察者间变异及巴黎尿细胞学系统进行了全面文献综述。

主要发现

  • 北美与欧洲病理医生在所用分级方案及低度恶性潜能乳头状尿路上皮肿瘤诊断上存在显著实践模式差异。
  • 共同点包括分级分配困难、希望改进分级标准以及倾向于细分高级别尿路上皮癌。

临床怎么用

  • 病理医生应了解当前分级系统的差异与共识方向,关注3级分级方案的细化趋势。
  • 在诊断低度恶性潜能乳头状尿路上皮肿瘤时需注意实践差异及意见不一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Grade is a key prognostic factor in determining progression in nonmuscle invasive papillary urothelial carcinomas. The 2 most common grading methods in use worldwide are the World Health Organization (WHO) 2004 and 1973 schemes. The International Society of Urological Pathology (ISUP) organized the 2022 consensus conference in Basel, Switzerland on current issues in bladder cancer and tasked working group 1 to make recommendations for future iterations of bladder cancer grading. For this purpose, the ISUP developed in collaboration with the European Association of Urology a 10-question survey for their memberships to understand the current use of grading schemes by pathologists and urologists and to ascertain the areas of potential improvements. An additional survey was circulated to the ISUP membership for their opinion on interobserver variability in grading, reporting of urine cytology, and challenges encountered in grade assignment. Comprehensive literature reviews were performed on bladder cancer grading prognosis and interobserver variability along with The Paris System for urine cytology. There are notable differences in practice patterns between North American and European pathologists in terms of used grading scheme and diagnosis of papillary urothelial neoplasm of low malignant potential. Areas of common ground include difficulty in grade assignment, a desire to improve grading criteria, and a move towards subclassifying high-grade urothelial carcinomas. The surveys and in-person voting demonstrated a strong preference to refine current grading into a 3-tier scheme with the division of WHO 2004 high grade into clinically relevant categories. More variable opinions were voiced regarding the use of papillary urothelial carcinoma with low malignant potential.

来源:Am J Surg Pathol,查看原文。版权归原作者所有。

引用

  1. Downes MR, Hartmann A, Shen S, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 1: Comparison of Bladder Cancer Grading System Performance. Am J Surg Pathol. 2023. PMID: 37246824. doi:10.1097/PAS.0000000000002059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。